EMPTY TRIALS, FADING DEMAND: THE COVID VACCINE LANDSCAPE IS CHANGING
About this episode
Confidence in COVID-19 vaccines in the United States appears to be shifting, as new developments point to declining public engagement and demand. A halted clinical study by Pfizer and BioNTech—reportedly due to an inability to recruit enough participants—marks a rare moment where a widely recommended vaccine could not generate sufficient interest for ongoing research.
This trend aligns with broader declines in vaccine uptake following the peak of the COVID-19 pandemic, as fewer individuals pursue boosters and participation in follow-up studies drops. The slowdown is also impacting pharmaceutical markets, which are seeing reduced demand compared to earlier stages of the rollout.
The recruitment challenges highlight evolving public sentiment and may signal a turning point in how COVID-19 vaccines are perceived, studied, and integrated into future public health strategies.
Get every episode summarized
Each time The Highwire publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
